CLIMB BIO INC (CLYM) — insider trading
Health Care · NASDAQ
CLIMB BIO INC (CLYM) has 13 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 13 (latest 2026-06-29).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Celebi Breanna Maurine | Director | Grant / award / vesting (derivative) | 70,284 | $0.00 | $0 | Form 4 |
| 2026-06-29 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 70,284 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Brennan Aoife | Director, Officer (President and CEO) | Open-market sale | 30,902 | $13.17 | $407.0K | Form 4 |
| 2026-06-27 | Brennan Aoife | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 68,750 | $0.00 | $0 | Form 4 |
| 2026-06-27 | Brennan Aoife | Director, Officer (President and CEO) | Option exercise / conversion | 68,750 | — | — | Form 4 |
| 2026-06-05 | Dunn Judith | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Thomas Stephen Basil | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Cumbo Alexander | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | WILLIAMS DOUGLAS E | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Drapkin Kimberlee C | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Levin Andrew David | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-04-29 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 2,106,000 | $9.50 | $20.01M | Form 4 |
Ask the chat about CLYM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CLIMB BIO INC (CLYM).
Last updated 2026-06-29 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.